|
|
 |
|
Viewing report
|
|
|
|
Pricing and Reimbursement Risk and Opportunities in Pharmaceutical Deal Making
PharmaVentures, July 2007, Pages: 88
“Understanding the world in which the customer operates and taking steps to bring your new product into that world with the customer’s workload in mind can enhance the adoption of new drugs.”
This report will focus on the critical application of the challenging political and market environment within the specific context of pricing and reimbursement (P&R) in the process of deal making.
The in-licensing of new drugs has increased dramatically over the past 30 years.
As deal making has intensified, the nature of deals has changed and issues such as market dynamics and the uncertainty around future pricing have increased in profile and can impact licensing deal valuation.
Where once a licensor would expect its new licensee partner to take responsibility for price setting and price expectations, now both parties need to increase their focus on the key price limitations that impact the deal value.
Valuation in deal making is not an exact science.
The message coming clearly from the pricing and reimbursement dynamics is that traditional models need frequent revision.
Health economic considerations that drive reimbursement decisions will play an increasing make-or-break role in new drug planning.
As deal making for unlicensed drugs grows in importance, so smarter deal making will become vital to the efficiency of the pharmaceutical business. P&R awareness is integral to that smarter deal making.
This report will teach you the key P&R drivers that shape tomorrow’s market.
You will learn what likely effects will surface from today’s political noise and be better prepared to anticipate product opportunity and maximise future success.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Orphan Drugs in Europe: Pricing, Reimbursement, Funding and Market Access Issues
Orphan Drug Strategies
Pricing & Reimbursement - Seven Major Markets Update
Pharmaceutical Pricing Strategies: Price optimization, reimbursement and regulation in Europe, US and Japan
Pharmaceutical Pricing and Reimbursement: Strategies for Market Access Across the US, Europe, Japan and Other Key Geographies
Strategic Overview of Pharmaceutical Pricing and Reimbursement in the Major Markets
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the First Quarter of 2008
The Pricing and Reimbursement Environment for Neurology Drugs
Special Report: Key Pricing and Reimbursement Trends for CNS Drugs
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Second Quarter of 2007
Pricing and Reimbursement Series: NICE its impact on the UK healthcare system and beyond
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Fourth Quarter of 2006
|
|
|
|
